


# World Journal of *Stem Cells*

*World J Stem Cells* 2012 October 26; 4(10): 101-109





## Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

### EDITOR-IN-CHIEF

LOscar Kuang-Sheng Lee, *Taipei*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*  
Andras Dinnyes, *Godollo*  
Umberto Galderisi, *Napoli*  
Mikhail G Kolonin, *Houston*  
Balazs Sarkadi, *Budapest*

### GUEST EDITORIAL BOARD

#### MEMBERS

Ing-Ming Chiu, *Miaoli*  
Chie-Pein Chen, *Taipei*  
Ju Jyh-Cherng, *Taichung*  
Hossein Hosseinkhani, *Taipei*  
Steven Shoen-Lung Li, *Kasohsiung*  
Tzu-Hao Wang, *Tao-Yuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Jeremy M Crook, *Melbourne*  
Alice Pébay, *Victoria*  
Kuldip S Sidhu, *Sydney*  
Ernst Wolvetang, *Brisbane*  
Xin-Fu Zhou, *Adelaide*



#### Austria

Ludwig Aigner, *Salzburg*



#### Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*  
Najimi Mustapha, *Brussels*



#### Brazil

Niels Olsen Saraiva Câmara, *São Paulo*  
Naiara Zoccal Saraiva, *Jaboticabal*



#### Canada

Borhane Annabi, *Montreal*  
Rosario Isasi, *Quebec*  
Xiao-Yan Jiang, *Vancouver*  
Seung U Kim, *Vancouver*  
Ren-Ke Li, *Toronto*  
Jeffrey A Medin, *Toronto*  
Kursad Turksen, *Ottawa*



#### China

Xiu-Wu Bian, *Chongqing*  
Yong Dai, *Shenzhen*  
Zhong-Chao Han, *Tianjin*  
Zhang Hao, *Beijing*  
Anskar YH Leung, *Hong Kong*  
Gang Li, *Hong Kong*  
Gui-Rong Li, *Hong Kong*  
Kai-Yan Liu, *Beijing*  
Yi-Jia Lou, *Hangzhou*  
Xue-Tao Pei, *Beijing*  
Jing-He Tan, *Tan-An*  
Jin-Fu Wang, *Hangzhou*  
Yun-Hai Zhang, *Hefei*



#### Czech Republic

Petr Dvorak, *Brno*  
Jaroslav Mokry, *Hradec Kralove*



#### Denmark

Basem M Abdallah, *Odense*  
Poul Maddox-Hyttel, *Frederiksberg*  
Lin Lin, *Tjele*  
Soren Paludan Sheikh, *Odense*



#### Finland

Jukka Partanen, *Helsinki*  
Petri Salven, *Helsinki*  
Heli Skottman, *Tampere*



#### France

Alain Chapel, *Paris*  
Gwendal Lazennec, *Montpellier*  
Muriel Perron, *Paris*  
Xavier Thomas, *Lyon*



#### Germany

James Adjaye, *Berlin*  
Christian Buske, *Ulm*  
Denis Corbeil, *Dresden*  
Frank Edenhofer, *Bonn*  
Ursula Margarethe Gehling, *Langen*  
Eric Gottwald, *Eggenstein-Leopoldshafen*  
Jorg Kleeff, *Munich*  
Gesine Kögler, *Düsseldorf*  
Nan Ma, *Rostock*  
Ulrich Martin, *Hannover*  
Heinrich Sauer, *Giessen*  
Richard Schäfer, *Tübingen*  
Sonja Schrepfer, *Hamburg*  
Wolfgang Wagner, *Aachen*

**Hungary**

Ferenc Uher, *Budapest*

**India**

Gurudutta U Gangenahalli, *Delhi*  
Asok Mukhopadhyay, *New Delhi*  
Anjali Suhas Shiras, *Maharashtra*

**Iran**

Masoud Soleimani, *Tehran*

**Israel**

Zeev Blumenfeld, *Haifa*  
Rachel Sarig, *Rehovot*  
Avichai Shimoni, *Tel-Hashomer*  
Shimon Slavin, *Tel Aviv*

**Italy**

Carlo Alberto Beltrami, *Udine*  
Clotilde Castaldo, *Naples*  
Carmelo Carlo-Stella, *Milano*  
Massimo Dominici, *Modena*  
Stefania Filos, *Naples*  
Angela Gritti, *Milano*  
Roberta Morosetti, *Rome*  
Felicita Pedata, *Florence*  
Anna Chiara Piscaglia, *Rome*  
Stefano Pluchino, *Milan*  
Caterina AM La Porta, *Milan*  
Domenico Ribatti, *Bari*

**Japan**

Tomoki Aoyama, *Kyoto*  
Susumu Ikehara, *Osaka*  
Taro Matsumoto, *Tokyo*  
Yuko Miyagoe-Suzuki, *Tokyo*  
Hiroyuki Miyoshi, *Tsukuba*  
Takashi Nagasawa, *Kyoto*  
Tetsuhiro Niidome, *Kyoto*  
Toshio Nikaido, *Toyama*  
Kohzo Nakayama, *Nagano*  
Tsukasa Ohmori, *Tochigi*  
Caterina AM La Porta, *Milan*  
Kumiko Saeki, *Tokyo*  
Kazunobu Sawamoto, *Aichi*  
Mikiko C Siomi, *Tokyo*  
Yoshiaki Sonoda, *Osaka*  
Takashi Tada, *Kyoto*  
Kotaro Yoshimura, *Tokyo*  
Louis Yuge, *Hiroshima*

**Netherlands**

Dirk Gijsbert de Rooij, *Amsterdam*

Christine Mummery, *Leiden*  
Frank JT Staal, *Leiden*  
Marten Piet Smidt, *Utrecht*

**Norway**

Brynjar Foss, *Stavanger*  
Berit Bølge Tysnes, *Bergen*

**Singapore**

Yu Cai, *Research Link*  
Tong Cao, *Singapore*  
Jerry Chan, *Singapore*  
Gavin Stewart Dawe, *Medical Drive*  
Chan Kwok-Keung Ken, *Singapore*  
Chan Woon Khiong, *Singapore*  
Steve KW Oh, *Singapore*  
Seeram Ramakrishna, *Singapore*  
Herbert Schwarz, *Singapore*  
Shu Wang, *Biopolis Way*

**South Korea**

Jong Wook Chang, *Seoul*  
Chong-Su Cho, *Seoul*  
Ssang-Goo Cho, *Seoul*  
Ho Jae Han, *Gwangju*  
Ki-Chul Hwang, *Seoul*  
Kyung-Sun Kang, *Seoul*  
Haekwon Kim, *Seoul*  
Hoeon Kim, *Daejeon*  
Mee Kum Kim, *Seoul*  
Yoon Jun Kim, *Seoul*  
Soo-Hong Lee, *Seoul*  
Dae-Sik Lim, *Daejeon*  
Byung Soon Park, *Seoul*  
Sun U Song, *Incheon*  
Seung Kwon You, *Seoul*

**Spain**

Fernando Cobo, *Granada*  
Sabrina C Desbordes, *Barcelona*  
Marta Muñoz Llamosas, *España*  
Maria P De Miguel, *Madrid*  
María Dolores Miñana, *Valencia*  
Felipe Prosper, *Navarra*

**Sweden**

M Quamrul Islam, *Linköping*  
Stefan Karlsson, *Lund*

**Switzerland**

Thomas Daikeler, *Basel*  
Sabrina Mattoli, *Basel*  
Arnaud Scherberich, *Basel*

**Turkey**

Alp CAN, *Ankara*  
Berna Arda, *Ankara*

**United Arab Emirates**

Sherif M Karam, *Al-Ain*

**United Kingdom**

Dominique Bonnet, *London*  
Kristin Mary Braun, *London*  
Wei Cui, *London*  
David C Hay, *Edinburgh*  
Wael Kafienah, *Bristol*  
Francis L Martin, *Lancaster*  
Mike Modo, *London*  
Donald Palmer, *London*  
Dame Julia Polak, *London*  
James Alexander Ross, *Edinburgh*  
Alastair James Sloan, *Cardiff*  
Virginie Sottile, *Nottingham*  
Hong Wan, *London*  
He-Ping Xu, *Aberdeen*  
Rike Zietlow, *Cardiff*

**United States**

Gregor Barr Adams, *Los Angeles*  
Kinji Asahina, *Los Angeles*  
Craig S Atwood, *Madison*  
Debabrata Banerjee, *New Brunswick*  
Aline M Betancourt, *New Orleans*  
Surinder Kumar Batra, *Omaha*  
Bruce Alan Bunnell, *New Orleans*  
Jason A Burdick, *Philadelphia*  
Anthony WS Chan, *Atlanta*  
Rebecca J Chan, *Indianapolis*  
G Rasul Chaudhry, *Rochester*  
Jonathan Donald Chesnut, *Carlsbad*  
Herman S Cheung, *Coral Gables*  
Kent W Christopherson II, *Chicago*  
David Wade Clapp, *Indianapolis*  
Rubin Clinton, *New York*  
Claudius Conrad, *Boston*  
Charles Samuel Cox, *Houston*  
Marcos de Lima, *Houston*  
Douglas C Dean, *Louisville*  
Goberdhan Dimri, *Evanston*  
David Dingli, *Rochester*  
Fu-Liang Du, *Vernon*  
Todd Evans, *New York*  
Toshihiko Ezashi, *Columbia*  
Vincent Falanga, *Alternate*  
Ira J Fox, *Pittsburgh*  
Markus Frank, *Boston*  
Sanga Gehmert, *Houston*  
Yong-Jian Geng, *Houston*  
Joseph C Glorioso, *Pittsburgh*  
Kristbjorn Orri Gudmundsson, *Frederick*  
Yan-Lin Guo, *Hattiesburg*  
Tong-Chuan He, *Chicago*  
Lorraine Iacovitti, *Philadelphia*  
Kunlin Jin, *Novato*

Michael R King, *Ithaca*  
 Uma Lakshmiopathy, *Carlsbad*  
 Hillard Michael Lazarus, *Shaker Heights*  
 Techung Lee, *Buffalo*  
 Robert C Miller, *Rochester*  
 Tao-Sheng Li, *Los Angeles*  
 Xiao-Nan Li, *Houston*  
 Ching-Shwun Lin, *San Francisco*  
 P Charles Lin, *Nashville*  
 Su-Ling Liu, *Ann Arbor*  
 Aurelio Lorico, *Las Vegas*  
 Jean-Pierre Louboutin, *Philadelphia*  
 Bing-Wei Lu, *Stanford*  
 Qing Richard Lu, *Dallas*  
 Nadya L Lumelsky, *Bethesda*  
 Hong-Bo R Luo, *Boston*  
 Hinh Ly, *Atlanta*  
 Teng Ma, *Tallahassee*  
 Kenneth Maiese, *Detroit*  
 Robert L Mauck, *Philadelphia*  
 Glenn Edwards McGee, *New York*  
 Murielle Mimeault, *Omaha*  
 Guo-Li Ming, *Baltimore*  
 Masato Nakafuku, *Cincinnati*  
 Christopher Niyibizi, *Hershey*  
 Seh-Hoon Oh, *Gainesville*  
 Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*  
 Derek A Persons, *Memphis*  
 Donald G Phinney, *Florida*  
 Donald George Phinney, *New Orleans*  
 Dimitris G Placantonakis, *New York*  
 George E Plopper, *Troy*  
 Derek Radisky, *Jacksonville*  
 Murugan Ramalingam, *Gaithersburg*  
 Pranela Rameshwar, *Newark*  
 Jeremy N Rich, *Cleveland*  
 Angie Rizzino, *Omaha*  
 Paul Ronald Sanberg, *Tampa*  
 Gerald Phillip Schatten, *Pittsburgh*  
 Ashok Kumar Shetty, *Durham*  
 Igor I Slukvin, *Madison*  
 Shay Soker, *Winston-Salem*  
 Hong-Jun Song, *Baltimore*  
 Kenichi Tamama, *Columbus*  
 Dean G Tang, *Smithville*  
 Hugh S Taylor, *New Haven*  
 Jonathan L Tilly, *Boston*  
 Jakub Tolar, *Minneapolis*  
 Deryl Troyer, *Manhattan*  
 Scheffer Chuei-Goong Tseng, *Miami*  
 Lyuba Varticovski, *Bethesda*  
 Tandis Vazin, *Berkeley*  
 Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*  
 Qi Wan, *Reno*  
 Charles Wang, *Los Angeles*  
 Guo-Shun Wang, *New Orleans*  
 Zack Z Wang, *Scarborough*  
 David Warburton, *Los Angeles*  
 Li-Na Wei, *Jackson Hall*  
 Andre Van Wijnen, *Worcester*  
 Marc Adrian Williams, *Rochester*  
 Joseph C Wu, *Stanford*  
 Li-Zi Wu, *Gainesville*  
 Sean M Wu, *Boston*  
 Yan Xu, *Pittsburgh*  
 Jun Yan, *Louisville*  
 Jing Yang, *Orange*  
 Li-Jun Yang, *Florida*  
 Phillip Chung-Ming Yang, *Stanford*  
 Pampee Paul Young, *Nashville*  
 Hong Yu, *Miami*  
 Seong-Woon Yu, *East Lansing*  
 Xian-Min Zeng, *Novato*  
 Bao-Hong Zhang, *Greenville*  
 Ying Zhang, *Baltimore*  
 Xue-Sheng Zheng, *Massachusetts*  
 X Long Zheng, *Philadelphia*  
 John F Zhong, *Los Angeles*



**ORIGINAL ARTICLE**

101

Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model

*Greish S, Abogresha N, Abdel-Hady Z, Zakaria E, Ghaly M, Hefny M*

## Contents

*World Journal of Stem Cells*  
Volume 4 Number 10 October 26, 2012

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Stem Cells*

**APPENDIX** I Meetings

I-V Instructions to authors

**ABOUT COVER** Greish S, Abogresha N, Abdel-Hady Z, Zakaria E, Ghaly M, Hefny M.  
Human umbilical cord mesenchymal stem cells as treatment of adjuvant  
rheumatoid arthritis in a rat model.  
*World J Stem Cells* 2012; 4(10): 101-109  
<http://www.wjgnet.com/1948-0210/full/v4/i10/101.htm>

**AIM AND SCOPE** *World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a Monthly open-access peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.  
The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

**FLYLEAF** I-III Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Shuai Ma*  
Responsible Electronic Editor: *Xiao-Mei Zheng*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Lei Wang*  
Proofing Editorial Office Director: *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Stem Cells*

**ISSN**  
ISSN 1948-0210 (online)

**LAUNCH DATE**  
December 31, 2009

**FREQUENCY**  
Monthly

**EDITING**  
Editorial Board of *World Journal of Stem Cells*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
Oscar Kuang-Sheng Lee, MD, PhD, Professor,

Medical Research and Education of Veterans General  
Hospital-Taipei, No. 322, Sec. 2, Shih-pai Road, Shih-  
pai, Taipei, 11217, Taiwan, China

**EDITORIAL OFFICE**  
Jian-Xia Cheng, Director  
Jin-Lei Wang, Vice Director  
*World Journal of Stem Cells*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai,  
Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
October 26, 2012

**COPYRIGHT**  
© 2012 Baishideng. Articles published by this Open-Ac-  
cess journal are distributed under the terms of the Cre-  
ative Commons Attribution Non-commercial License,  
which permits use, distribution, and reproduction in any  
medium, provided the original work is properly cited, the  
use is non commercial and is otherwise in compliance  
with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the view-  
points of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165700.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esps/>

## Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model

Sahar Greish, Noha Abogresha, Zeinab Abdel-Hady, Eman Zakaria, Mona Ghaly, Mohamed Hefny

Sahar Greish, Noha Abogresha, Department of Physiology, Faculty of Medicine, Suez Canal University, 4111 Ismailia, Egypt  
Zeinab Abdel-Hady, Department of Histology, Faculty of Medicine, Suez Canal University, 4111 Ismailia, Egypt  
Eman Zakaria, Department of Pharmacology, Faculty of Medicine, Suez Canal University, 4111 Ismailia, Egypt  
Mona Ghaly, Mohamed Hefny, Department of Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, 4111 Ismailia, Egypt

**Author contributions:** All authors contributed equally to this work; Hefny M, Ghaly M and Greish S designed the research; Greish S and Abogresha N prepared the stem cells; Abdel-Hady Z performed the histopathology; Zakaria E induced arthritis in rats and injected treatment; Hefny M and Ghaly M analyzed the data and wrote the paper; all authors revised the final version of the paper.

**Correspondence to:** Mona Ghaly, Lecturer, Department of Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, 4111 Ismailia, Egypt. [xmghaly@gmail.com](mailto:xmghaly@gmail.com)  
Telephone: +20-11-43516507 Fax: +20-64-3230539  
Received: July 27, 2012 Revised: August 23, 2012  
Accepted: September 18, 2012  
Published online: October 26, 2012

### Abstract

**AIM:** To investigate the effect of human umbilical cord stem cells, both mesenchymal and hematopoietic (CD34+), in the treatment of arthritis.

**METHODS:** Mesenchymal stem cells (MSCs) and hematopoietic (CD34+) stem cells (HSC) were isolated from human umbilical cord blood obtained from the umbilical cord of healthy pregnant donors undergoing full-term normal vaginal delivery. MSC, HSC, methotrexate (MTX) and sterile saline were injected intra-articularly into the rat hindpaw with complete Freund's adjuvant (CFA) induced arthritis after the onset of disease (day 34), when arthritis had become well established (arthritis score  $\geq 2$ ). Arthritic indices were evaluated and the levels of interleukin (IL)-1, tumor necrosis factor (TNF)- $\alpha$  and interferon (IFN)- $\gamma$  and anti-inflammatory cytokine

IL-10 in serum were determined using enzyme-linked immunosorbent assay. Animals of all groups were sacrificed 34 d after beginning treatment, except positive control (PC) which was sacrificed at 10, 21 and 34 d for microscopic observation of disease progression. We used hematoxylin, eosin and Masson's trichrome stains for histopathological examination of cartilage and synovium.

**RESULTS:** The mean arthritis scores were similar in all groups at 12 and 34 d post immunization, with no statistical significant difference. Upon the injection of stem cells (hematopoietic and mesenchymal), the overall arthritis signs were significantly improved around 21 d after receiving the injection and totally disappeared at day 34 post treatment in MSC group. Mean hindpaw diameter (mm) in the MSC rats was about half that of the PC and MTX groups ( $P = 0.007$  and  $P = 0.021$ , respectively) and 0.6 mm less than the HSC group ( $P = 0.047$ ), as indicated by paw swelling. Associated with these findings, serum levels of TNF- $\alpha$ , IFN- $\gamma$  and IL-1 decreased significantly in HSC and MSC groups compared to PC and MTX groups ( $P < 0.05$ ), while the expression of IL-10 was increased. Histopathological examination with H and E stain revealed that the MTX treated group showed significant reduction of leucocytic infiltrate and hypertrophy of the synovial tissue with moderate obliteration of the joint cavity. Stem cells treated groups (both hematopoietic CD34+ and mesenchymal), showed significant reduction in leucocytic infiltrate and hypertrophy of the synovial tissue with mild obliteration of the joint cavity. With Masson's trichrome, stain sections from the PC group showed evidence of vascular edema of almost all vessels within the synovium in nearly all arthritic rats. Vacuoles were also visible in the outer vessel wall. The vessel became hemorrhagic and finally necrotic. In addition, there was extensive fibrosis completely obliterating the joint cavity. The mean color area percentage of collagen in this group was  $0.324 \pm 0.096$ , which was significantly increased when compared to the negative control group.

The mean color area percentage of collagen in hematopoietic CD34+ and mesenchymal groups was  $0.176 \pm 0.0137$  and  $0.174 \pm 0.0197$  respectively, which showed a marked decrement compared to the PC group, denoting a mild increase in synovial tissue collagen fibers.

**CONCLUSION:** MSC enhance the efficacy of CFA-induced arthritis treatment, most likely through the modulation of the expression of cytokines and amelioration of pathological changes in joints.

© 2012 Baishideng. All rights reserved.

**Key words:** Complete freunds adjuvant-induced arthritis; Human umbilical mesenchymal stem cell; Hematopoietic stem cell; CD34+

Greish S, Abogresha N, Abdel-Hady Z, Zakaria E, Ghaly M, Hefny M. Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model. *World J Stem Cells* 2012; 4(10): 101-109 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v4/i10/101.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v4.i10.101>

## INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune disease caused by loss of immunological self-tolerance that leads to chronic inflammation in the joints and subsequent cartilage destruction and bone erosion. The crucial process underlying disease initiation is the induction of autoimmunity to collagen-rich joint components; later events evolve a destructive inflammatory process<sup>[1]</sup>. In RA, pro-inflammatory cytokines, such as tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6, IL-1 and IL-17, play dominant pathological roles. Aberrant T helper cells (Th) 17 and Th1 responses have been linked to pathogenesis of RA<sup>[2-4]</sup>. Furthermore, evidence is accumulating that a defect in number or function of regular T cells is important in the immune imbalance that culminates in RA<sup>[5,6]</sup>.

RA imparts a massive burden on health services worldwide. A desirable therapeutic approach would be to prevent the activation of inflammatory and autoimmune components of the disease<sup>[6-10]</sup>. Efforts to discover new target therapies have achieved considerable success. For instance, TNF- $\alpha$  inhibitors and B-cell-depleting therapies have benefited many RA patients<sup>[7]</sup>. However, these approaches are expensive and none of the currently widely used biological agents reaches long-term drug-free remission<sup>[8,9]</sup>. Therefore, it is important to develop a new and more effective therapy for RA.

Mesenchymal stem cells (MSCs) are mesoderm-derived cells that reside in the stroma of solid organs and function as precursors of nonhematopoietic connective tissues<sup>[11,12]</sup>. They can exert profound immunosuppression by modulating T and B cell proliferation and differentiation, dendritic cell maturation and NK activity.

These immunoregulatory properties encourage a possible use of these cells to modulate autoimmune responses and in the treatment of autoimmune diseases<sup>[13]</sup>. Several recent studies have shown that bone marrow-derived MSCs (BM-MSCs) regulate the immune response, including *in vitro* inhibition of T cell proliferation, B cell function and dendritic cell maturation<sup>[14]</sup>.

However, the specific molecular and cellular mechanisms involved in the immunoregulatory activity of BM-MSCs remain a subject of controversy<sup>[15-18]</sup>. In addition, aspirating bone marrow is an invasive procedure. In addition, the number and the differentiating potential of BM-MSCs decrease with age<sup>[19,20]</sup>. Human umbilical cord blood-derived MSCs (hUCB-MSCs) have a capacity similar to that of BM-MSCs for multi-lineage differentiation<sup>[21]</sup>. In addition, hUCB-MSCs also possess activities for immune modulation, tumor tropism and nursing effect<sup>[22,23]</sup>.

Recent evidence has demonstrated that hUCB-MSCs can suppress, not only the function of mature dendritic cells, but also increase the portion of regulatory T cells related to immune regulation<sup>[24,25]</sup>. In fact, hUCB-MSCs have much higher chondrogenic differentiation potential among mesodermal differentiation potentials, which might lead to regeneration of damaged cartilage. These properties might be due in part to specific secreted factors, including some types of cytokines and growth factors. For instance, it has been reported that thrombospondin-1, 2 functions as an anti-inflammatory factor in RA by suppressing production of proinflammatory mediators, such as interferon (IFN)- $\gamma$  and TNF- $\alpha$ , inducing depletion of synovium residing T cells and reducing infiltration of monocytes/macrophages in articular tissues<sup>[26,27]</sup>. However, very little is known about UC-MSCs, with one report about UC-MSCs in the treatment of RA<sup>[28]</sup>.

Consequently, to understand and utilize the immune regulation properties of hUCB-MSCs for application in the treatment of a number of human immunological diseases, the molecular mechanism underlying the immune modulatory functions of hUCB-MSCs needs further investigations.

## MATERIALS AND METHODS

This study was performed in the Stem Cell Unit in the Physiology Department, Faculty of Medicine, Suez Canal University. It was performed according to the national laws on animal experiments and with the permission of the local university ethics commission. We used forty apparently healthy male rats weighing 100-150 g in this study. We purchased the rats from the National Centre of Research (Cairo, Egypt), housed in clean cages under hygienic conditions and allowed to acclimatize for 7 d before starting the experiment. Rats were kept on a standard chow and water ad libitum with a reversed dark-light cycle. All possible measures were made to minimize animal suffering and to reduce the number of used animals.

Animals were randomly divided into five groups each of eight rats: negative control (NC), positive control (PC), methotrexate (MTX), MSC and hematopoietic (CD34+) stem cells (HSC).

### Induction of RA

RA was induced in all groups (except NC), in briefly anaesthetized rats, using a single intradermal injection of 0.1 mL complete freunds adjuvant (CFA) (Sigma, United Kingdom) into the right hindpaw<sup>[29]</sup>. Rats were monitored for signs of arthritis onset based on paw swelling and clinical scores<sup>[30]</sup>. Paw swelling was assessed by measuring the mean thickness of both hindpaws with 0-10-mm calipers. Clinical arthritis was scored on a scale of 0-4, where 0 = no swelling, 1 = redness, 2 = swelling, 3 = digit deformity, and 4 = ankle deformity (ankylosis). All clinical score (CS) measurements were performed independently by two individuals, without awareness of the rats' clinical score history. Full ankylosis was scored clinically by lack of motion of the extremity in question. An animal could have a CS of 16 if all paws were fully ankylosed.

### Preparation of stem cells

**Umbilical cord blood samples collection:** After obtaining informed consent, hUCB samples were obtained from the umbilical cord of healthy pregnant donors undergoing full-term normal vaginal delivery. Females with a history of hepatitis, infectious diseases, diabetes mellitus, severe hypertension, abortions or abnormal obstetric history were excluded. UCB was collected while the placenta was in utero. By strict aseptic techniques, 50 mL of hUCB were withdrawn from the umbilical vein and collected in sterile tubes containing five milliliters of citrate phosphate dextrose adenine-1 anticoagulant and stored at 4 °C in a refrigerator and processed within 24 h<sup>[31]</sup>.

**Umbilical cord blood samples processing:** Cord blood sample was diluted 1:1 with isolation buffer. A 3.0 mL histopaque-1077 was placed in a 15 mL centrifuge tube and brought to room temperature, then 6 mL diluted blood was carefully layered onto the histopaque-1077 and centrifuged at  $400 \times g$  for exactly 30 min at normal room temperature. After centrifugation, we carefully aspirated the upper layer with a Pasteur pipet to within 0.5 cm of the opaque interface containing mononuclear cells and it was discarded. The opaque interface was carefully transferred to a clean centrifuge tube with a Pasteur pipet. About 6-10 mL isolation buffer was added to the tube and was mixed by gentle aspiration, then centrifuged at  $400 \times g$  for 20 min. We aspirated and discarded the supernatant. Then, the cell pellet was suspended with 5.0 mL isolation buffer and mixed by gentle aspiration with a Pasteur pipet and then centrifuged at  $400 \times g$  for 10 min. The previous steps were repeated three times; each time supernatant was discarded and cell pellet was suspended in 0.5 mL isolation buffer. The quantity of the isolated mononuclear cells was assessed by automated cell counter

and the viability was determined by a trypan blue exclusion test.

**Separation and purification of CD34+ cells:** Separation of UCB CD34+ stem cells was carried out according to the method described by an immuno-magnetic separation technique<sup>[32]</sup>. By mixing and incubation, CD34+ cells were bound to Dynabeads M-450 CD34. The formed rosettes were isolated from the suspension using a DYNAL Magnetic Particle Concentrator (DYNAL MPC). Subsequent incubation with DETACHaBEAD, CD34 gently detached isolated cells from the beads. A DYNAL MPC was then used to separate the purified, positively selected CD34+ cells from the released Dynabeads M-450 CD34. The quantity of the isolated CD34+ cells was assessed by putting the sample in an automated cell counter. The quality of the isolated CD34+ cells was determined by using a trypan blue dye exclusion test where the viable cells were not stained<sup>[33]</sup>.

**Culture of MSC from mononuclear cells:** MSCs isolation is possible due to its capacity of adhesion to the flasks. Cultures were initiated in culture flasks of 25 cm<sup>2</sup> at a density of  $1.0 \times 10^6$  mononuclear cells/cm<sup>2</sup>. Cells were nurtured with culture medium  $\alpha$ -MEM supplemented with 20% fetal bovine serum, 1% antibiotic/antimycotic and 1% glutamine, then incubated at 37 °C, humidified atmosphere containing 5% CO<sub>2</sub>. After overnight incubation, non-adherent cells were removed and fresh medium was added to the culture flask. Later on, the culture medium was changed every 4 d and cellular growth assessed daily under an inverted microscope. When the cells reached 50%-60% confluence, they were detached with 0.25% trypsin-EDTA (Invitrogen), the trypsin was inactivated with fresh media, and the cells centrifuged at 250 g for 5 min<sup>[34]</sup>.

### Treatment

Treatment was begun after the onset of disease (day 34), when arthritis had become well established (arthritis score  $\geq 2$ ). All rats in four groups received a single intra-articular injection in the right hindpaw where the NC and PC group rats received 5  $\mu$ L sterile saline, 0.9% PBS, the MSC group received  $1 \times 10^6$  MSCs, and the HSC group received  $1 \times 10^6$  hematopoietic stem cell. However, MTX received 0.3 mg/kg twice a week for 5 wk.

### Histopathological analysis of synovium and cartilage

Animals in all groups were sacrificed 34 d after beginning treatment, except the PC group. Animals of the PC group were divided equally and sacrificed at 10, 21 and 34 d for microscopic observation of disease progression.

At the end of the experiment, according to each group schedule, hindpaws were taken from skinned sacrificed animals and placed in 10% buffered phosphate formalin for at least 1 wk before being subjected to acid decalcification. The paws were decalcified by immersion in 3% nitric acid solution and maintained at room tem-

perature for an average of 5-7 d. De-calcified paws were embedded in paraffin, longitudinally sectioned through the center of the tibia-tarsal joint, and stained with hematoxylin and eosin and Masson's trichrome. Quantitative measurements were carried out using the image analyzer (Super eye-Heidi soft) to measure the color area percentage of the green color (collagen fibers) in Masson's trichrome stained sections. The image analyzer was calibrated for color before utilization. Thirty fields, at least, were captured and analyzed for each group.

### Cytokine assay

TNF- $\alpha$ , IL-1, IL-10 and IFN- $\gamma$  were estimated 34 d after beginning treatment in the rat serum by sandwich enzyme-linked immunosorbent assays using capture/biotinylated detection antibodies (Sigma, United Kingdom).


### Statistical analysis

Student's *t* test was used to analyze significance between groups. A *P* value of less than 0.05 was considered a significant difference.

## RESULTS


To study the therapeutic effect of MSC and HSC, we first established adjuvant arthritis rat models according to established protocol. The arthritis that develops in rats after a single intradermal treatment with CFA shows a rapid clinical progression. Animals showed clinical signs of disease starting from day 10-12 after immunization with CFA; these initial signs were restricted to redness in one or both hindpaws. These early clinical signs of disease rapidly progressed to swelling, digit deformity and finally to hindpaw ankylosis in 100% of immunized rats by day 34. Figure 1A compares the gross appearance of a normal rat hindpaw and a fully ankylosed hindpaw from a CFA-immunized rat at day 34. Incidence of forepaw involvement in immunized animals was lower and more variable than the hindpaw disease, affecting 20%-90% of rats and generally after day 21. We examined the immune-suppression effect of stem cells on the CFA mouse models by injecting MSC, HSC, MTX or PBS into rats once paw swelling had fully developed (34 d post immunization). Grossly, we found that the swelling of those rats receiving PBS further worsened or showed no significant improvement. The mean arthritis score was similar in all groups at 12 and 34 d post immunization with no statistical significant difference. Mean arthritis score was assessed in all groups at 44, 55 and 68 d post immunization (10, 21 and 34 d post treatment) and results revealed a significant decrease in both MSC and HSC groups compared to MTX and PC groups, started at 55 d post immunization and reached its maximum at day 68. In addition, there was a statistical significant difference between MSC and HSC groups at day 68 ( $P = 0.036$ ) (Figure 1B).

We observed that paw swelling in rats of the HSC and MSC groups began to disappear around 21 d after receiving stem cell injection and totally disappeared at




**Figure 1 Decreased severity of complete freunds adjuvant induced arthritis after treatment with human umbilical cord blood-derived mesenchymal stem cells.** A: compares the gross appearance of a normal rat hindpaw and a fully ankylosed hindpaw from a complete freunds adjuvant (CFA)-immunized rat at day 34; B: Rats with established CFA injected intra-articular with 5  $\mu$ L sterile saline, 0.9% PBS in positive control (PC),  $1 \times 10^6$  mesenchymal stem cell (MSC) in MSC group and  $1 \times 10^6$  hematopoietic stem cell in hematopoietic (CD34+) stem cell (HSC) group and 0.3 mg/kg twice a week for 5 wk in methotrexate (MTX) group. Arthritis severity was assessed by clinical scoring at day 12, 34, 44, 55, 68 post-immunization with CFA; C: mean hind paw diameter was determined at day 12, 34, 44, 55, 68 post immunization with CFA. <sup>a</sup> $P < 0.05$  MSC vs control, <sup>c</sup> $P < 0.05$  MSC vs MTX group; <sup>e</sup> $P < 0.05$  MSC vs HSC group.

day 34 post treatment in the MSC group. The mean hind-paw diameter (mm) in the MSC rats was about half that of the PC and MTX groups ( $P = 0.007$  and  $P = 0.021$ , respectively) and 0.6 mm less than the HSC group ( $P = 0.047$ ) (Figure 1C).



**Figure 2 Photomicrograph of rat.** A: Negative control group showed intact articular cartilage (C) with normal joint cavity (JC) and synovial tissue (ST) (HE,  $\times 400$ ); B: Photomicrograph of a rat from positive control group showed that hypertrophy and massive mononuclear cell infiltration of the synovial tissue; C: Hypervascularity, congestion, mononuclear cells infiltration (arrows) within vessels (V) wall and rheumatoid nodules (RN); D, E: Inflammatory granulation tissue (arrows) completely obliterated the joint space and; F: Inflammatory granulation tissue (arrows) eroded the articular cartilage (C) and subchondral bone. HE,  $\times 200$ .



**Figure 3 Photomicrograph of rat from methotrexate group (A), CD34 group (B) and mesenchymal group (C).** A: Reduction of leucocytic infiltrate and hypertrophy of the synovial tissue (arrows) with moderate obliteration of joint cavity (JC); B: Reduction of leucocytic infiltrate and hypertrophy of the synovial tissue (arrows) with mild obliteration of JC; C: Reduction of leucocytic infiltrate and hypertrophy of the synovial tissue (arrows) with mild obliteration of JC. HE,  $\times 200$ .

### Results of histopathology


H and E stained sections in hindpaws of the NC group showed intact articular cartilage with normal joint space and synovial tissue (Figure 2A). Sections from the PC group showed a microscopic analysis of disease progression in CFA-immunized rats. The first histological signs of disease appeared at day 10, when hypertrophy of the synovial lining was observed. Massive mononuclear cell infiltration of the synovium was also visible in the same section (Figure 2B).

Nearly, all arthritic rats showed evidence of hypervascularity and congestion. Mononuclear cells infiltration was also visible within vessels wall (Figure 2C). Chronic inflammatory nodules and rheumatoid nodules in the synovial connective tissue of arthritic rats were also found. These nodule-like structures have a defined morphology, consisting of a central zone composed of necrotic tissue and polymorphonuclear cells, surrounded by a layer of radially oriented mononuclear cells (Figure 2C). With disease progression, by day 21 the synovial tissue became

hypercellular and well vascularized, so that, at this stage, the synovial lining had been replaced by an inflammatory granulation tissue, or pannus obliterating the joint space (Figure 2D and E). By day 34, infiltrating pannus significantly eroded the articular cartilage and subchondral bone (Figure 2F), both from the joint margins and the periarticular space, resulting in complete fibrous ankylosis.

The MTX group showed significant reduction of leucocytic infiltrate and hypertrophy of the synovial tissue with moderate obliteration of the joint cavity (Figure 3A). However, stem cells treatment, both CD34+ (HSC) (Figure 3B) and mesenchymal (MSC) (Figure 3C), showed more or less similar results, with significant reduction of leucocytic infiltrate and hypertrophy of the synovial tissue with mild obliteration of joint cavity.

With Masson's trichrome stain, the NC group showed a normal synovial tissue with delicate collagen fibers (Figure 4A). The mean color area percentage of collagen in this group was  $0.121 \pm 0.0147$  (Table 1). Sections



**Figure 4** Photomicrograph of rat from negative control group (A), positive control group (B), positive control group (C), methotrexate group (D), CD34 group (E) and mesenchymal group (F). A: Negative control group showed synovial tissue with delicate collagen fibers (arrows) (Masson's trichrome,  $\times 400$ ); B: Positive control (PC) group showed vascular edema and vacuoles (arrows) within vessels (V) of the synovial tissue (Masson's trichrome  $\times 200$ ); C: PC group showed extensive fibrosis (arrows) completely obliterating the joint cavity (Masson's trichrome,  $\times 200$ ); D: Methotrexate group showed moderate increase in collagen fibers (arrows) of the synovial tissue (Masson's trichrome,  $\times 200$ ); E: CD34 group showed mild increase in collagen fibers (arrows) of the synovial tissue (Masson's trichrome,  $\times 200$ ); F: Mesenchymal group showed mild increase in collagen fibers (arrows) of the synovial tissue (Masson's trichrome,  $\times 200$ ).

**Table 1** The mean color area percentage of green collagen in the different experimental group

Group	mean $\pm$ SD
Negative control	0.121 $\pm$ 0.0147
Positive control	0.324 $\pm$ 0.096 <sup>b</sup>
Methotrexate	0.183 $\pm$ 0.0148 <sup>d</sup>
Hematopoietic (CD34+)	0.176 $\pm$ 0.0137 <sup>d</sup>
Mesenchymal	0.174 $\pm$ 0.0197 <sup>d</sup>

<sup>b</sup> $P < 0.01$  vs negative control group; <sup>d</sup> $P < 0.001$  vs positive control group.

from the PC group showed evidence of vascular edema of almost all vessels within the synovium in nearly all arthritic rats. Vacuoles were also visible in the outer vessel wall (Figure 4B). The vessel became hemorrhagic and finally necrotic. This histological progression resembles necrotizing vasculitis seen in human RA. Sections from the same group also showed extensive fibrosis completely obliterating the joint cavity (Figure 4C). The mean color area percentage of collagen in this group was  $0.324 \pm 0.096$ , which was significantly increased when compared to the control group (Table 1).

The MTX group revealed a moderate increase in collagen fibers in the synovial tissue (Figure 4D). The mean color area percentage of collagen in this group was  $0.183 \pm 0.0148$ , which was significantly increased compared to the NC group; however, it was markedly decreased compared to the PC group (Table 1). Stem cell treatment, both HSC (Figure 4E) and MSC (Figure 4F), showed similar results with a mild increase in collagen fibers in the synovial tissue. The mean color area percentage of collagen in the HSC and MSC groups was  $0.176 \pm 0.0137$  and  $0.174 \pm 0.0197$  respectively, which was significantly increased

when compared to the NC group; however, it was markedly decreased compared to the PC group (Table 1).


### Results of cytokine assay

In addition, the results of immunoassay showed that the serum levels of TNF- $\alpha$ , IL-1 and IFN- $\gamma$  were lower in the HSC and MSC groups compared to the PC and MTX groups ( $P < 0.05$ ). Both groups also showed elevated anti-inflammatory cytokine IL-10 in comparison to PC and MTX. Despite the level of these cytokines being lower in the MSC group than the HSC group, this difference was not statistically significant (Figure 5A and B).

## DISCUSSION

Analysis of the histopathology of CFA induced arthritis in rat shows the progression of arthritic disease resembling human RA. These similarities support the use of CFA injected rat as an appropriate model for testing potential therapeutics for the treatment of RA<sup>[35]</sup>.

Generally, MSCs have an immune suppressive function in addition to its roles in tissue repair. In addition, they have the capability of self-renewal and differentiation into different lineages of mesenchymal tissues. Moreover, MSCs have been consistently shown to exert a potent immunosuppressive effect superior in magnitude to any other immunosuppressive cell types thus far described<sup>[36]</sup>. Compared with those BM-MSCs, hUCB-MSCs have higher proliferative potency, lower risk for viral contamination and stronger differentiation capacity<sup>[34]</sup>. Several researchers have conducted studies to demonstrate the therapeutic potential of BM-MSCs for RA<sup>[37,38]</sup>, but few studies have reported on hUCB-MSCs.



**Figure 5** Inhibition of inflammatory responses in rats with complete freunds adjuvant induced arthritis after treatment with human umbilical cord blood-derived mesenchymal stem cells. A: Levels of tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-1, and interferon (IFN)- $\gamma$  in the sera of rats in positive control (PC) group, methotrexate (MTX) group, mesenchymal stem cell (MSC) group and hematopoietic (CD34+) stem cell (HSC) group obtained on day 34; B: Serum level of IL-10 obtained from different groups on day 34. <sup>a</sup> $P < 0.05$  MSC vs control and MTX groups; <sup>c</sup> $P < 0.05$  HSC vs control and MTX groups.

Zhou *et al.*<sup>[39]</sup> found that human MSC could significantly inhibit the autoimmune progression in MRL/lpr mice. In our study, we further researched the possible clinical utility of hUCB-MSCs in the treatment of RA. Grossly, we noticed that injection of human umbilical cord blood-derived stem cells (both mesenchymal and hematopoietic) into CFA rats led to a significant reduction in the severity of arthritis. Paw swelling had completely disappeared 21-34 d after stem cell administration, but with a significant decrease in the MSC group, more than the PC group, MTX group and even the HSC group.

These results were in accordance with Fei Mao and his colleagues<sup>[37]</sup>, who found that injection of MSCs into collagen induced arthritis mice led to a significant reduction in arthritic signs with complete disappearance of paw swelling 21 d after MSC administration in CIA/MSC mice.

Microscopically, in HE stained sections there was a significant reduction of leucocytic infiltrate and hypertrophy of the synovial tissue with mild obliteration of the joint cavity in both HSC and MSC groups in comparison to the PC and MTX group. These findings were similar to Liu *et al.*<sup>[28]</sup>, who observed that control mice exhibited a marked mononuclear cell infiltration, severe synovitis, pannus formation and bone erosion, while the majority of joints from mice injected with umbilical cord-MSCs had normal morphology with a smooth articulation cartilage surface and an absence of inflammatory cell infiltrate and pannus formation.

With Masson's trichrome stain there was a mild increase in collagen fibers in the synovial tissue in both HSC and MSC groups and a moderate increase in the MTX group, denoting that the increase in collagen fibers and fibrosis associated with RA had been decreased with stem cell injection. In addition, these changes were also in favor of the MSC group, more than HSC, suggesting that MSC may be a more potent therapeutic in alleviating the arthritic burden, even more than HSC. In conclusion, we observe that microscopically, human umbilical MSCs can prevent tissue damage in RA.

Furthermore, we investigated the effect of stem cells on production of inflammatory mediators that are linked to RA and found that HSC and MSC injections significantly downregulated TNF- $\alpha$ , IL-1 and IFN- $\gamma$ , as well as upregulated the regulatory and anti-inflammatory cytokine (IL-10). These results are consistent with previous findings by others<sup>[37]</sup> showing the immunosuppressive effect of MSCs and our results showed that human umbilical stem cells can be a potent candidate for therapeutic treatment for RA.

In conclusion, many new therapeutic possibilities for RA have been proposed recently. Most of these target individual proinflammatory cytokines or cytokine-producing cells as anti-TNF drugs. Here, we believe that human umbilical MSCs could be a better therapeutic option for the treatment of RA.

## COMMENTS

### Background

Rheumatoid arthritis (RA) is an autoimmune disease that leads to chronic inflammation in the joints and subsequent cartilage destruction and bone erosion. RA imparts a massive burden on health services worldwide. A desirable therapeutic approach would be to prevent the destructive effects of RA. New target therapies have achieved considerable success; however, these approaches are expensive and none of the currently widely used biological agents reaches long-term drug-free remission. Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) have a potential capacity to regulate the immune response, including *in vitro* inhibition of T cell proliferation, B cell function and dendritic cell maturation.

### Research frontiers

hUCB-MSCs are regarded as an alternative source of bone marrow-derived MSCs because collection of cord blood is less invasive than that of bone marrow. In addition, hUCB-MSCs also possess activities for immune modulation, tumor tropism and nursing effect. However, very little is known about hUCB-MSCs in the treatment of RA. Consequently, to understand and use the immune regulation properties of hUCB-MSCs for application in the treatment of a number of human immunological diseases, the molecular mechanism underlying the immune modulatory functions of hUCB-MSCs should be further investigated.

### Innovations and breakthroughs

In this study, the authors tried to understand and utilize the immune regulation properties of hUCB-MSCs for the treatment of RA.

### Applications

The study results suggest that MSCs enhance the efficacy of complete freunds

adjuvant-induced arthritis treatment, most likely through the modulation of the expression of inflammatory cytokines and amelioration of joint damage.

### Terminology

RA is a chronic systemic inflammatory disease of unknown cause. The hallmark feature of this condition is persistent symmetric polyarthritis (synovitis) that affects the hands and feet, although any joint lined by a synovial membrane may be involved. Extra-articular involvement of organs such as the skin, heart, lungs and eyes can be significant. hUCB-MSCs, isolated from the umbilical cord of healthy pregnant donors undergoing full-term normal vaginal delivery, are a promising candidate source of MSCs. Apart from their prominent advantages of abundant supply, painless collection and faster self-renewal, hUCB-MSCs have shown the potencies to differentiate into a variety of cells of three germ layers (such as bone, cartilage, adipose, skeletal muscle, cardiomyocyte, endothelium, hepatocyte-like cluster, islet-like cluster, neuron, astrocyte and oligodendrocyte).

### Peer review


This is interesting work that is in line with other findings in induced arthritis models.

## REFERENCES

- 1 Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature* 2003; **423**: 356-361
- 2 Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. *J Immunol* 2003; **171**: 6173-6177
- 3 Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribbling P, Shu J, Lee WP, Refino CJ, Balazs M, Palerm-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL. Targeted depletion of lymphotoxin- $\alpha$ -expressing TH1 and TH17 cells inhibits autoimmune disease. *Nat Med* 2009; **15**: 766-773
- 4 Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. *Arthritis Rheum* 2007; **56**: 531-543
- 5 Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF $\alpha$  therapy. *J Exp Med* 2004; **200**: 277-285
- 6 Morgan ME, Suttmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, de Vries RR, Toes RE. CD25 $^{+}$  cell depletion hastens the onset of severe disease in collagen-induced arthritis. *Arthritis Rheum* 2003; **48**: 1452-1460
- 7 Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell* 2008; **133**: 775-787
- 8 Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, de Vries RR, Toes RE. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25 $^{+}$  regulatory T cells. *Arthritis Rheum* 2005; **52**: 2212-2221
- 9 van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Tams LS. CD4 $^{+}$ CD25 $^{+}$  regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. *Arthritis Rheum* 2004; **50**: 2775-2785
- 10 Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4 $^{+}$  T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. *Arthritis Rheum* 2000; **43**: 617-627
- 11 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; **284**: 143-147
- 12 Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001; **7**: 211-228
- 13 Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. *Stem Cells* 2009; **27**: 1421-1432
- 14 Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 2005; **106**: 1755-1761
- 15 Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. *Blood* 2007; **110**: 3499-3506
- 16 Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. *Exp Hematol* 2002; **30**: 42-48
- 17 Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood* 2005; **105**: 2821-2827
- 18 Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* 2005; **105**: 2214-2219
- 19 Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. *Mech Ageing Dev* 2008; **129**: 163-173
- 20 Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. *Mech Ageing Dev* 2001; **122**: 713-734
- 21 Gang EJ, Jeong JA, Hong SH, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim H. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. *Stem Cells* 2004; **22**: 617-624
- 22 Bieback K, Klüter H. Mesenchymal stromal cells from umbilical cord blood. *Curr Stem Cell Res Ther* 2007; **2**: 310-323
- 23 Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J, Kim SK. Targeting rat brain-stem glioma using human neural stem cells and human mesenchymal stem cells. *Clin Cancer Res* 2009; **15**: 4925-4934
- 24 Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, Xu J. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. *Immunology* 2009; **126**: 220-232
- 25 Hao L, Zhang C, Chen XH, Zou ZM, Zhang X, Kong PY, Liang X, Gao L, Peng XG, Sun AH, Wang QY. Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro. *Croat Med J* 2009; **50**: 351-360
- 26 Rimo MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. *J Cell Physiol* 2007; **211**: 504-512
- 27 Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. *Am J Pathol* 2004; **165**: 2087-2098
- 28 Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. *Arthritis Res Ther* 2010; **12**: R210
- 29 Barsante MM, Roffè E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, Castro MS, Teixeira MM. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. *Eur J Pharmacol* 2005; **516**: 282-289
- 30 Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. *Nat Med* 2001; **7**: 563-568

- 31 **Wagner JE.** Umbilical cord blood stem cell transplantation. *Cancer Treat Res* 1995; **76**: 195-213
- 32 **Miltenyi S, Müller W, Weichel W, Radbruch A.** High gradient magnetic cell separation with MACS. *Cytometry* 1990; **11**: 231-238
- 33 **Strober W.** Trypan blue exclusion test of cell viability. *Curr Protoc Immunol* 2001; **Appendix 3**: Appendix 3B
- 34 **Secco M, Zucconi E, Vieira NM, Fogaça LL, Cerqueira A, Carvalho MD, Jazedje T, Okamoto OK, Muotri AR, Zatz M.** Multipotent stem cells from umbilical cord: cord is richer than blood! *Stem Cells* 2008; **26**: 146-150
- 35 **Pearson CM.** Development of arthritis, periarthritis and periostitis in rats given adjuvants. *Proc Soc Exp Biol Med* 1956; **91**: 95-101
- 36 **Uccelli A, Moretta L, Pistoia V.** Immunoregulatory function of mesenchymal stem cells. *Eur J Immunol* 2006; **36**: 2566-2573
- 37 **Mao F, Xu WR, Qian H, Zhu W, Yan YM, Shao QX, Xu HX.** Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. *Inflamm Res* 2010; **59**: 219-225
- 38 **Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WU, Oh IH, Cho CS.** Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. *Clin Exp Immunol* 2008; **153**: 269-276
- 39 **Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L.** Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. *Cell Mol Immunol* 2008; **5**: 417-424

**P-Reviewer** Driscoll D   **S-Editor** Wen LL   **L-Editor** Roemmele A  
**E-Editor** Zheng XM



## Acknowledgments to reviewers of World Journal of Stem Cells

We acknowledge our sincere thanks to our reviewers. Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of our World Series Journals. Both the editors of the journals and authors of the manuscripts submitted to the journals are grateful to the following reviewers for reviewing the articles (either published or rejected) over the past period of time.

**Markus Frank, MD, Assistant Professor**, Harvard Medical School, Transplantation Research Center, Children's Hospital Boston, Enders Research Building Room 816, 300 Longwood Avenue, Boston, MA 02115, United States

**Alice Pébay, PhD**, Centre for Neuroscience and Department of Pharmacology, University of Melbourne, Parkville VIC 3010, Australia

**Zhong-Chao Han, MD, PhD, Professor**, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

**Hiroyuki Miyoshi, PhD**, Subteam for Manipulation of Cell Fate, BioResourceCenter, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

**Heli Teija Kristiina Skottman, PhD**, Academy of Finland Research fellow, Regea Institute for Regenerative medicine, University of Tampere, Finland, Biokatu 12, 33520 Tampere, Finland

**Soren Paludan Sheikh, MD, PhD, Professor**, Department of Biochemistry, Pharmacology and Genetics, Odense Univ-

ersity Hospital, University of Southern Denmark, Sdr. Boulevard 29, DK 5000, Denmark

**Ludwig Aigner, PhD, Professor**, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

**Borhane Annabi, PhD, Professor**, Department of Chemistry, Biomed Research Centre, Université du Québec à Montréal Montreal, Quebec, H2X 2J6, Canada

**Denis Corbeil, PhD**, Tissue Engineering Laboratories, Biotech, Medical Faculty, Technical University of Dresden, Tatzberg 47-49, 01307 Dresden, Germany


**Mieke Geens, PhD**, EMGE, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium

**Xiao-Yan Jiang, MD, PhD, Associate Professor**, Medical Genetics, University of British Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

**John F Zhong, PhD, Assistant Professor**, School of Medicine, University of Southern California, 2025 Zonal Ave, RMR 210, Los Angeles, CA 90033, United States

**Hong Yu, PhD**, Miami VA Health Care System, 1201 NW 16th St, Research 151, Miami, FL 33125, United States

**Andre Van Wijnen, PhD**, Department of Cell Biology, Rm S3-322, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States



## Events Calendar 2012

January 22-27, 2012

Keystone Symposia: Cardiovascular  
Development and Regeneration  
Taos, NM, United States

February 2-3, 2012

Stem Cells 2012  
San Diego, CA, United States

February 16, 2012

The 2012 London Regenerative  
Medicine Event  
London, United Kingdom

February 23, 2012

CiRA Symposium: Advances in  
Nuclear Reprogramming and Stem  
Cell Research  
Kyoto, Japan

February 26 - March 2, 2012

Gordon Research Conference:  
Reprogramming Cell Fate  
Galveston, TX, United States

March 9, 2012

Cell Culture Technology: Recent  
Advances, Future Prospects  
London, United Kingdom

March 11-16, 2012

Keystone Symposia: The Life of a  
Stem Cell: From Birth to Death  
Olympic Valley (Lake Tahoe),  
CA, United States

March 25-30, 2012

Keystone Symposia: Advances in  
Islet Biology  
Monterey, CA, United States

March 28-29, 2012

Single Cell Analysis Europe  
Edinburgh, United Kingdom

April 1 - 6, 2012

Keystone Symposia: Mechanisms  
of Whole Organ Regeneration,  
joint with Regenerative Tissue  
Engineering and Transplantation  
Breckenridge, CO, United States

April 25-28, 2012

3rd International Congress on  
Responsible Stem Cell Research  
Aula Nuova del Sinodo  
Vatican City, Vatican City

April 27-29, 2012

2nd Institute of Advanced Dental  
Sciences & Research International  
Conference 2012: Fundamentals of  
Conducting and Reporting Research-  
Biological, Pharmaceutical, Medical  
& Dental Sciences  
University of the Punjab, Lahore,  
Pakistan

April 29 - May 2, 2012

3rd International Conference on  
Stem Cell Engineering (ICSCE)  
Co-organized by the Society for  
Biological Engineering (SBE) and the  
ISSCR  
Seattle, WA, United States

April 30, 2012

Stem Cells to Tissues  
Boston, MA, United States

April 30, 2012

Regenerative Biology: From Stem  
Cells to Tissues  
The Joseph B Martin Conference  
Center, Harvard Medical School  
Boston, MA, United States

April 30-May 2, 2012

Till & McCulloch Meetings  
Montreal, QC, Canada

May 18, 2012

The 2012 Stem Cell Discussion  
Forum  
London, United Kingdom

May 21-22, 2012

Driving Stem Cell Research Towards  
Therapy.  
Edinburgh, United Kingdom

June 5-8, 2012

18th Annual International Society  
for Cellular Therapy Meeting  
Washington, DC, United States

June 13-16, 2012

International Society for Stem Cell  
Research 10th Annual Meeting  
Yokohama, Japan

June 25-27, 2012

The Stem Cell Niche - development  
and disease  
Copenhagen, Denmark

June 27-28, 2012

Bioprocessing & Stem Cells Europe  
London, United Kingdom

June 28-29, 2012

Origins of Tissue Stem Cells  
Edinburgh, United Kingdom

July 9-11, 2012

Stem Cells in Cancer - 2nd annual  
Cambridge Stem Cell International  
Symposium  
Cambridge, United Kingdom

July 15-18, 2012

39th Annual Meeting & Exposition  
of the Controlled Release Society  
Smart Materials - From Innovation  
to Translation  
Centre des Congrès de Québec,  
Québec City, Canada

August 29 - September 1, 2012

EMBL Conference: Stem Cells in  
Cancer and Regenerative Medicine  
Heidelberg, Germany

September 5-8, 2012


TERMIS World Congress 2012  
Vienna, Austria

October 15-17 2012

13th World Congress of the  
International Society for Diseases of  
the Esophagus  
Venice, Italy

November 6, 2012

Stem Cells and Metabolism  
The Salk Institute of Biological  
Studies La Jolla,  
CA, United States



## INSTRUCTIONS TO AUTHORS

### GENERAL INFORMATION

*World Journal of Stem Cells* (World J Stem Cells, WJSC, online ISSN 1948-0210, DOI: 10.4252), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

#### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of WJSC and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since WJSC is an OA journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from WJSC official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the

maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

#### Aims and scope

The major task of WJSC is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. WJSC is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in WJSC will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

#### Columns

The columns in the issues of WJSC will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in stem cells; (9) Brief Articles: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in WJSC, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in stem cells.

#### Name of journal

*World Journal of Stem Cells*

#### ISSN

ISSN 1948-0210 (online)

#### Editor-in-Chief

**Oscar Kuang-Sheng Lee, MD, PhD, Professor**, Medical Research and Education of Veterans General Hospital-Taipei, No. 322, Sec. 2, Shih-pai Road, Shih-pai, Taipei, 11217, Taiwan, China

#### Editorial Office

*World Journal of Stem Cells*

Editorial Department: Room 903, Building D,  
Ocean International Center, No. 62 Dongsihuan Zhonglu,  
Chaoyang District, Beijing 100025, China

## Instructions to authors

E-mail: [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com)  
<http://www.wjgnet.com>  
Telephone: +86-10-85381891  
Fax: +86-10-85381893

### Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, etc. The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, WJSC requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines

Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165700.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjsc@wjgnet.com](mailto:wjsc@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

**Title page**

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

**Abstract**

There are unstructured abstracts (no less than 256 words) and

structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

**Key words**

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

**Text**

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1948-0210/g\\_info\\_list.htm](http://www.wjgnet.com/1948-0210/g_info_list.htm).

**Illustrations**

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

**Tables**

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

**Notes in tables and illustrations**

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

**Acknowledgments**

Brief acknowledgments of persons who have made genuine con-

## Instructions to authors

tributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Pleased provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

**Electronic journal** (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

**Patent** (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pres-

sure,  $p(B) = 16.2/12.3$  kPa; incubation time,  $t(\text{incubation}) = 96$  h, blood glucose concentration,  $c(\text{glucose}) = 6.4 \pm 2.1$  mmol/L; blood CEA mass concentration,  $p(\text{CEA}) = 8.6 \pm 24.5$   $\mu\text{g/L}$ ;  $\text{CO}_2$  volume fraction, 50 mL/L  $\text{CO}_2$ , not 5%  $\text{CO}_2$ ; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313172144.htm](http://www.wjgnet.com/1948-0210/g_info_20100313172144.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities:  $t$  time or temperature,  $c$  concentration,  $A$  area,  $l$  length,  $m$  mass,  $V$  volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindII*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

### Examples for paper writing

**Editorial:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313165833.htm](http://www.wjgnet.com/1948-0210/g_info_20100313165833.htm)

**Frontier:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170509.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170509.htm)

**Topic highlight:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170618.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170618.htm)

**Observation:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170727.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170727.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313170855.htm](http://www.wjgnet.com/1948-0210/g_info_20100313170855.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171012.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171012.htm)

**Review:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171124.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171124.htm)

**Original articles:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171239.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171239.htm)

**Brief articles:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171358.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171358.htm)

**Case report:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171504.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171504.htm)

**Letters to the editor:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171613.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171613.htm)

**Book reviews:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171713.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171713.htm)

**Guidelines:** [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313171803.htm](http://www.wjgnet.com/1948-0210/g_info_20100313171803.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system via the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313172045.htm](http://www.wjgnet.com/1948-0210/g_info_20100313172045.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1948-0210/g\\_info\\_20100313172000.htm](http://www.wjgnet.com/1948-0210/g_info_20100313172000.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

WJSC will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

WJSC is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.